Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Study Summary

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.

Conditions

Metastatic Melanoma Squamous Cell Carcinoma of the Head and Neck Non-small Cell Lung Cancer

Interventions / Drugs

Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab Nivolumab-relatlimab Cisplatin Carboplatin Paclitaxel Nab-Paclitaxel Pemetrexed

View on ClinicalTrials.gov ↗

Sponsor

IOVA

Iovance Biotherapeutics

Cell Therapy

C64/100

Study Details

Enrollment245 participants

Primary Completion—

Lead SponsorIovance Biotherapeutics, Inc.

Data Retrieved2026-04-11 04:17:54.732702+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.